Krempa David (CIK 1968254) reported 16 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-13). Recent activity: Buy ETON (10,000 shares), Buy ETON (12,476 shares), Buy ETON (30,591 shares), Sell ETON (32,963 shares), Sell ETON (9,315 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-13 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Buy | 10,000 | $0 |
| 2026-05-27 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Buy | 12,476 | $17,092 |
| 2026-05-27 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Buy | 30,591 | $109,516 |
| 2026-05-27 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Sell | 32,963 | $1.1M |
| 2026-05-27 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Sell | 9,315 | $315,594 |
| 2026-05-27 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Sell | 519 | $18,165 |
| 2026-05-27 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Buy | 25,000 | $34,500 |
| 2026-05-27 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Buy | 12,524 | $17,158 |
| 2026-05-27 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Sell | 37,524 | $1.2M |
| 2026-05-27 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Buy | 7,203 | $25,787 |
| 2026-05-27 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Sell | 19,679 | $619,375 |
| 2026-01-14 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Sell | 1,942 | $30,334 |
| 2025-12-12 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Sell | 6,264 | $106,488 |
| 2025-06-16 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Sell | 16,977 | $253,297 |
| 2025-06-16 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Sell | 6,800 | $100,436 |
| 2025-06-16 | Eton Pharmaceuticals, Inc. (ETON) | Chief Business Officer | Sell | 10,223 | $150,585 |
Source: SEC Form 4 filings · as of 2026-07-13